Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
NGNE Neurogene	$19.19 +28.4%	$17.49	$6.88 ▼ $74.49	$213.22M	1.51	249,857 shs	1.35 million shs
PAHC Phibro Animal Health	$26.62 +4.2%	$22.99	$16.16 ▼ $26.77	$1.04B	0.75	211,012 shs	271,863 shs
VERV Verve Therapeutics	$11.28 +0.4%	$6.41	$2.86 ▼ $11.51	$1.00B	2.21	2.43 million shs	4.13 million shs
WVE WAVE Life Sciences	$6.51 +0.2%	$6.71	$5.04 ▼ $16.74	$1.01B	-1.01	1.27 million shs	1.27 million shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
NGNE Neurogene	+28.36%	+11.57%	+11.50%	+83.46%	-52.76%
PAHC Phibro Animal Health	+4.23%	+7.47%	+8.30%	+21.55%	+56.22%
VERV Verve Therapeutics	+0.45%	+0.98%	+154.63%	+188.49%	+126.51%
WVE WAVE Life Sciences	+0.15%	-4.69%	+7.07%	-14.00%	+24.36%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
NGNE Neurogene	3.5128 of 5 stars	4.4	3.0	0.0	0.0	1.4	1.7	1.3
PAHC Phibro Animal Health	3.6491 of 5 stars	0.8	2.0	2.5	1.1	3.0	3.3	2.5
VERV Verve Therapeutics	3.4972 of 5 stars	4.2	4.0	0.0	0.0	1.8	3.3	0.0
WVE WAVE Life Sciences	4.3684 of 5 stars	3.5	1.0	0.0	4.8	2.2	4.2	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
NGNE Neurogene	2.75	Moderate Buy	$46.17	140.58% Upside
PAHC Phibro Animal Health	1.67	Reduce	$21.80	-18.11% Downside
VERV Verve Therapeutics	2.33	Hold	$14.57	29.18% Upside
WVE WAVE Life Sciences	2.92	Moderate Buy	$20.50	214.90% Upside

Current Analyst Ratings Breakdown

Latest NGNE, WVE, VERV, and PAHC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/27/2025	VERV Verve Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform	$20.00 ➝ $13.50
6/26/2025	VERV Verve Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/25/2025	PAHC Phibro Animal Health	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Equal Weight ➝ Equal Weight	$21.00 ➝ $26.00
6/23/2025	WVE WAVE Life Sciences	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$18.00
6/18/2025	VERV Verve Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$28.00 ➝ $11.00
6/18/2025	VERV Verve Therapeutics	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$12.00
6/18/2025	VERV Verve Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$13.50
6/17/2025	NGNE Neurogene	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$50.00
6/17/2025	VERV Verve Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Market Perform
6/17/2025	VERV Verve Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$39.00 ➝ $13.00
6/16/2025	PAHC Phibro Animal Health	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold

(Data available from 7/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
NGNE Neurogene	$930K	294.25	N/A	N/A	$20.89 per share	0.92
PAHC Phibro Animal Health	$1.02B	1.06	$2.20 per share	12.08	$6.34 per share	4.20
VERV Verve Therapeutics	$32.33M	31.10	N/A	N/A	$5.83 per share	1.93
WVE WAVE Life Sciences	$108.30M	9.35	N/A	N/A	$1.37 per share	4.75

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
NGNE Neurogene	-$75.14M	-$4.35	N/A	N/A	N/A	N/A	-36.16%	-32.51%	8/8/2025 (Estimated)
PAHC Phibro Animal Health	$2.42M	$0.78	34.13	12.68	0.48	2.68%	30.51%	6.89%	8/27/2025 (Estimated)
VERV Verve Therapeutics	-$198.71M	-$2.11	N/A	N/A	N/A	-303.64%	-35.81%	-27.57%	8/14/2025 (Estimated)
WVE WAVE Life Sciences	-$97.01M	-$0.84	N/A	N/A	N/A	N/A	-86.49%	-37.20%	8/6/2025 (Estimated)

Latest NGNE, WVE, VERV, and PAHC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	VERV Verve Therapeutics	-$0.71	-$0.35	+$0.36	-$0.35	$7.13 million	$32.98 million
5/9/2025	Q1 2025	NGNE Neurogene	-$1.05	-$1.08	-$0.03	-$1.08	N/A	N/A
5/8/2025	Q1 2025	WVE WAVE Life Sciences	-$0.27	-$0.29	-$0.02	-$0.29	$11.65 million	$9.18 million
5/7/2025	Q3 2025	PAHC Phibro Animal Health	$0.52	$0.63	+$0.11	$0.51	$352.41 million	$347.80 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
NGNE Neurogene	N/A	N/A	N/A	N/A	N/A
PAHC Phibro Animal Health	$0.48	1.80%	N/A	61.54%	N/A
VERV Verve Therapeutics	N/A	N/A	N/A	N/A	N/A
WVE WAVE Life Sciences	N/A	N/A	N/A	N/A	N/A

Latest NGNE, WVE, VERV, and PAHC Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/6/2025	PAHC Phibro Animal Health	quarterly	$0.12	2.52%	6/4/2025	6/4/2025	6/25/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
NGNE Neurogene	N/A	21.03	21.03
PAHC Phibro Animal Health	2.67	2.91	1.23
VERV Verve Therapeutics	N/A	9.84	9.84
WVE WAVE Life Sciences	N/A	2.95	2.95

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
NGNE Neurogene	52.37%
PAHC Phibro Animal Health	99.34%
VERV Verve Therapeutics	97.11%
WVE WAVE Life Sciences	89.73%

Insider Ownership

Company	Insider Ownership
NGNE Neurogene	9.92%
PAHC Phibro Animal Health	50.07%
VERV Verve Therapeutics	19.30%
WVE WAVE Life Sciences	23.98%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
NGNE Neurogene	90	14.26 million	12.85 million	Optionable
PAHC Phibro Animal Health	1,940	40.53 million	20.24 million	Optionable
VERV Verve Therapeutics	110	89.14 million	71.94 million	Optionable
WVE WAVE Life Sciences	240	155.56 million	118.26 million	Optionable

NGNE, WVE, VERV, and PAHC Headlines

Recent News About These Companies

WAVE Life Sciences (NASDAQ:WVE) Given Outperform Rating at Wedbush

June 24, 2025 | americanbankingnews.com

Where WAVE Life Sciences Stands With Analysts

June 23, 2025 | benzinga.com

WAVE Life Sciences (NASDAQ:WVE) Receives "Outperform" Rating from Wedbush

June 23, 2025 | marketbeat.com

Wave Life Sciences Announces Oral Presentation of Preclinical Data Supporting WVE-007's Mechanism (INHBE) to Reduce Fat, Preserve Muscle, and Induce Healthy Weight Loss at ADA ...

June 22, 2025 | manilatimes.netM

Wave Life Sciences Presents Promising Preclinical Data for WVE-007, a Novel siRNA Obesity Treatment at American Diabetes Association Meeting

June 22, 2025 | nasdaq.com

Wave Life Sciences Announces Oral Presentation of Preclinical Data Supporting WVE-007’s Mechanism (INHBE) to Reduce Fat, Preserve Muscle, and Induce Healthy Weight Loss at ...

June 20, 2025 | finance.yahoo.com

Wave Life Sciences Announces Oral Presentation of Preclinical Data Supporting WVE-007's Mechanism (INHBE) to Reduce Fat, Preserve Muscle, and Induce Healthy Weight Loss at ADA's Annual Scientific Sessions

June 20, 2025 | globenewswire.com

WAVE Life Sciences (NASDAQ:WVE) Stock Price Down 6.8% - Should You Sell?

June 20, 2025 | marketbeat.com

WAVE Life Sciences (NASDAQ:WVE) Shares Cross Below 50-Day Moving Average - Time to Sell?

June 19, 2025 | marketbeat.com

Wave Life Sciences Ltd. (NASDAQ:WVE) Director Sells $208,500.00 in Stock

June 14, 2025 | insidertrades.com

Wave Life Sciences Ltd. (NASDAQ:WVE) Director Gregory L. Verdine Sells 30,000 Shares

June 13, 2025 | marketbeat.com

Wave Life Sciences (NASDAQ:WVE) Now Covered by Raymond James

June 11, 2025 | marketbeat.com

Wave Life Sciences Ltd. (NASDAQ:WVE) Receives Average Recommendation of "Buy" from Analysts

June 11, 2025 | marketbeat.com

Brokers Offer Predictions for WVE FY2026 Earnings

June 10, 2025 | marketbeat.com

Wave Life Sciences (NASDAQ:WVE) Shares Down 4.6% - Here's Why

June 9, 2025 | marketbeat.com

Two Sigma Advisers LP Buys Shares of 68,100 Wave Life Sciences Ltd. (NASDAQ:WVE)

June 3, 2025 | marketbeat.com

Universal Beteiligungs und Servicegesellschaft mbH Acquires Shares of 362,291 Wave Life Sciences Ltd. (NASDAQ:WVE)

June 2, 2025 | marketbeat.com

Wave Life Sciences to Present at 2025 Jefferies Global Healthcare Conference

May 29, 2025 | globenewswire.com

Wave Life Sciences Announces Appointment of Dr. Christopher Wright as Chief Medical Officer

May 28, 2025 | globenewswire.com

Is Wave Life Sciences (WVE) the Best Low Priced Biotech Stock to Buy Now?

May 13, 2025 | msn.com

Wave Life Sciences Ltd. (WVE) Q1 2025 Earnings Call Transcript

May 9, 2025 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NGNE, WVE, VERV, and PAHC Company Descriptions

Neurogene NASDAQ:NGNE

$19.19 +4.24 (+28.36%)

Closing price 07/1/2025 04:00 PM Eastern

Extended Trading

$19.50 +0.31 (+1.62%)

As of 08:05 AM Eastern

Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.

Phibro Animal Health NASDAQ:PAHC

$26.62 +1.08 (+4.23%)

Closing price 07/1/2025 04:00 PM Eastern

Extended Trading

$26.60 -0.02 (-0.06%)

As of 04:04 AM Eastern

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.

Verve Therapeutics NASDAQ:VERV

$11.28 +0.05 (+0.45%)

Closing price 07/1/2025 04:00 PM Eastern

Extended Trading

$11.26 -0.02 (-0.22%)

As of 08:00 AM Eastern

Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

WAVE Life Sciences NASDAQ:WVE

$6.51 +0.01 (+0.15%)

Closing price 07/1/2025 04:00 PM Eastern

Extended Trading

$6.78 +0.27 (+4.07%)

As of 08:00 AM Eastern

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time